Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

AEterna releases interim phase I/II data for Psovascar

Sep. 14, 1998

Immune Response presents phase II data on psoriasis treatment

Sep. 11, 1998

RXR/RAR receptor modulators claimed by CIRD Galderma for skin and other disorders

Sep. 9, 1998

Biotech Australia announces encouraging early clinical trial results with leg ulcer treatment

Sep. 4, 1998

Leo describes potent vitamin D3 derivatives with low calcemic activity

Sep. 3, 1998

Keratinocyte growth factor to enter phase II clinical trials

Sep. 3, 1998

Access signs development agreement with ViroTex for amlexanox formulations

Sep. 1, 1998

Access signs licensing agreement with Paladin to market amlexanox in Canada

Aug. 27, 1998

Incert appears to prevent the formation of postoperative adhesions

Aug. 26, 1998

Toray reports kappa agonists for treating dermatological disorders

Aug. 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...